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Abstract
Purpose. Histogenesis of synovial sarcoma remains controversial and reliable molecular markers for diagnosis are necessary.
Expression of basic calponin, a smooth muscle differentiation-speci® c actin-binding protein, was studied in synovial sarcoma.
Subjects and Methods. The basic calponin gene and the gene product were analyzed by reverse transcription PCR analysis
(RT-PCR) and immunohistochemistry in 14 synovial sarcomas and a human synovial sarcoma cell line (HS-SY-II).
Results and Discussion. Immunoreactivity for basic calponin was detected in the cytoplasm of 6 synovial sarcomas (43%
positive). In the basic calponin-positive tumors and the HS-SY-II cells, expression for smooth muscle-speci® c genes,
including basic calponin and SM22a , was detected by RT-PCR, suggesting a lineage relationship between synovial sarcoma
cells and smooth muscle-like mesenchymal cells.
Conclusions. A subset of synovial sarcomas expressing the basic calponin gene and the gene product were identi® ed. The
basic calponin may have potential utility as a novel molecular marker identifying certain synovial sarcomas.
Key words: calponin, synovial sarcoma, myoepithelium, smooth muscle.
Introduction
Synovial sarcomas, which account for approximately
10% of soft tissue tumors, arise most commonly in
the para-articular regions in adolescents and young
adults.
1The lineage of differentiation or histogenesis
still remains controversial,
2,3 including the synovial,
4
epithelial,
5neural,
6and primitive mesenchymal
1 cells
in origin. Positive immunostaining for cytokeratin
and/or epithelial membrane antigen as well as
vimentin has been applied for diagnosis,
1 but
histological differential diagnosis may be difficult in
the poorly differentiated cases. Therefore, additional
genetic or phenotypic markers seem to be necessary
to identify synovial sarcoma and predict the biological
behaviors of the tumors.
Basic calponin is an actin-, tropomyosin- and
calmodulin-binding protein originally isolated from
smooth muscle.
7,8 Structural analysis of cDNAs
encoding calponin isoforms has revealed the pres-
ence of three types of genes with distinct expres-
sional regulation.
7,9,10 Each of the three calponin
genes encodes distinct classes of isoforms categorized
into basic (pI 8 to 10), neutral (pI 7 to 8) and acidic
(pI 5 to 6) calponins on the basis of their isoelectric
points. Although the neutral and acidic calponins are
expressed in both smooth muscle and non-smooth
muscle tissues,
9,11 the basic calponin gene is one of
the earliest markers of differentiated smooth muscle
cells.
12± 15
Recently, expression of basic calponin has proved
not to be restricted solely to smooth muscle cells, and
has been detected also in cells that present with certain
smooth muscle-like phenotypes, i.e.myo® broblasts and
myoepithelial cells expressing a set of other smooth
muscle markers.
16,17 With regard to tumors, expres-
sion of basic calponin was detected in leiomyomas,
18
leiomyosarcomas,
19,20 and a subset of osteosarco-
mas.
21
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basic calponin expression to synovial sarcoma using
the tumor samples and a cultured cell line (HS-SY-
II).
22 We identi® ed a subset of synovial sarcomas
expressing the basic calponin gene and the gene
product.
Materials and methods
Tumor tissues
Tumor samples listed in Table 1 were obtained from
primary tumors in 14 patients with synovial sarcoma
and in 51 patients with other soft-tissue sarcomas at
the Department of Orthopaedic Surgery, Osaka
Medical Center for Cancer and Cardiovascular
Diseases.The histologic diagnoses and subtypes were
established through routine pathologic evaluation
according to the published criteria.
1 Diagnosis of
synovial sarcoma was con® rmed by expression of the
SYT-SSX fusion gene resulting from the chromosomal
translocation.
23,24 The SYT-SSX fusion gene was
detected previously for 8 of 14 synovial sarcomas,
25
and for the remaining 6 synovial sarcomas in this
study. Clinical and pathological data of the patients
with synovial sarcoma are summarized in Table 2. All
synovial sarcomas were considered high grade and
deep-seated. Histologic subtypes were as follows;
monophasic type: 10 cases, biphasic type: 4 cases.
The specimens were ® xed in 10% formalin/PBS and
embedded in paraffin. Sections of 4 m m thickness
were prepared for staining with hematoxylin-eosin,
and for immunohistochemical examination.
Synovial sarcoma cell line
A human synovial sarcoma cell line (HS-SY-II),
22
which showed a characteristic chromosomal translo-
cation t(X;18)(p11;q11), was cultured in Dulbecco’s
modi® ed Eagle’s medium (DMEM) (Life Tech.,
Gaithersburg, USA) supplemented with 10% (v/v)
fetal bovine serum (Upstate Biotech.,Waltham, USA)
and 1% penicillin/streptomycin at 37Ê C under a
humidi® ed atmosphere containing 5% (v/v) CO2.
Cells in a logarithmic phase of proliferation were
collected and served for detection of mRNAs.
Immunohistochemistry
Monoclonal antibodies against basic calponin (clone
hCP) and a -smooth muscle actin (a -SMA)(clone
1A4) were obtained from Sigma Chemicals (St Louis,
USA). The speci® city of the clone hCP monoclonal
antibody to basic calponin isoform was veri® ed as
described previously.
11,21The sections were mounted
on poly-L-lysin coated microslides, deparaffinized in
xylene, dehydrated through graded alcohol, and
immersed in 70% methanol with H2O2 to block
endogenous peroxidase. Antigen retrieval for basic
calponin was performed using a 400-W microwave
oven (TOSHIBA ERT 330) for 5 min (4 times) in a
10 mM citrate buffer (pH 7.0). The sections were
incubated with 1% (v/v) goat serum/PBS for 1 h at
room temperature, washed in PBS, and incubated
with the antibody in 2% (w/v) BSA/PBS overnight at
4Ê C. They were then washed 5 times with 0.005%
(v/v) Tween 20/PBS, followed by incubation with the
biotinylated goat anti-mouse IgG (TAGO Immuno-
logicals, Camarillo, USA) in 2% (w/v) BSA/PBS for
1 h at room temperature and avidin± biotin±
horseradish peroxidase complex (Vector Laboratories,
Burlingame, CA) for 30 min at room temperature.
After being washed in 0.005% (v/v) Tween 20/PBS,
the ® nal reaction product was visualized with diami-
nobenzidine (WAKO Chemicals, Osaka, Japan), and
the sections were counterstained with hematoxylin.
Negative control study with mouse non-immune IgG
was included to assess non-speci® c staining.All assays
were scored by three independent observers; staining
levels were graded with regard to the number of posi-
tive cells in a given tumor sample (++; 50± 95% posi-
tive cells, +; 10± 45% positive cells; ± ; less than 10%
positive cells).
Reverse transcription-PCR analysis
Tumor tissues were frozen immediately after surgical
removal and stored at ± 80Ê C until extraction of RNA.
Total RNA was extracted from tumor tissues using
the RNA extraction kit (Nippon Gene, Toyama,
Japan). Reverse transcription (RT) of 2 m g of total
RNA was carried out using reaction mixture of Ready-
To-Go You-Prime First-Strand Beads (Pharmacia
Table 1. Immunohistochemical analyses of smooth muscle calponin and a -smooth muscle actin in soft tissue sarcomas
Calponin positive a -SMA positive
Diagnosis No. 2+ 1+ - rate (%) 2+ 1+ - rate (%)
Synovial sarcoma 14 3 3 8 43 0 0 14 0
Malignant ® brous histiocytoma 11 0 1 10 9 1 4 6 45
Leiomyosarcoma 8 4 2 2 75 5 3 0 100
Liposarcoma 8 0 1 7 13 0 0 8 0
Malignant schwannoma 7 0 1 6 14 0 0 7 0
Rhabdomyosarcoma 5 0 0 5 0 0 0 5 0
Alveolar soft-part sarcoma 5 0 0 5 0 0 0 5 0
Dermato® brosarcoma 3 0 0 3 0 0 1 2 33
Angiosarcoma 2 0 0 2 0 0 0 2 0
Epithelioid sarcoma 2 0 0 2 0 0 0 2 0
108 Hidefumi Ono et al.Biotech., Uppsala, Sweden) in the presence of 0.2 m g
of the random hexaprimers pd(N)6. After 60 min
incubation at 37Ê C, 0.5 m M of each of the forward
and reverse primers, 200 m M of each dNTP mix and
2.5 U of Taq DNA polymerase (Pharmacia Biotech.)
were added to 8 m l of the ® rst strand reaction mixture
and then, total volume was adjusted to 50 m l with
water.The parameters used for the ampli® cation were
30 cycles of denaturation (94Ê C, 40 s), annealing
(60Ê C, 30 s) and polymerization (72Ê C, 90 s).
Sequences of the selected forward and reverse primers
used, and predicted products size were as follows:
SYT-SSX, CAACAGCAAGATGCATACCA
(forward), CACTTGCTATGCACCTGATG
(reverse), 585 bp;
25 basic calponin, GAGTGTGCA-
GACGGAACTTCAGCC (forward), GTCTGT-
GCCCAACTTGGGGTC (reverse), 671 bp;
21
neutral calponin, CTGCAGAGCGGGGTGGA-
CATTGGC, (forward) GCCGGCCTCCTCCT-
GGTAGTAAGG (reverse), 519 bp;
21acidic calponin,
GGAAGCGAAGTGCGAGAGACC (forward),
CTGTGTGGATCTAATAATCAATGC (reverse),
1061 bp;
21 SM22a , CGCGAAGTGCAGTC-
CAAAATCG (forward), GGGCTGGTTCTTCT-
TCAATGGGG (reverse), 928 bp;
26 glyceraldehyde
3-phosphate dehydrogenase (GAPDH), CCCAT-
CACCATCTTCCAGGA (forward), TTGTCAT-
ACCAGGAATGAGC (reverse), 731 bp.
21 The
linearity of the PCR products for SYT-SSX,
calponins, and SM22a was obtained between 25± 30
cycles and for GAPDH between 20± 25 cycles. After
agarose gel (1%) electrophoresis in the presence of
0.5 mg/ml of ethidium bromide, the PCR products
were revealed by UV irradiation, and the image
captured, digitized and quantitated by Eagle Eye II
Still Video System (Stratagene, La Jolla, USA). Vari-
ations in signal intensities between different agarose
gels were corrected by using signal intensities of the
molecular weight markers in every gel analyzed. Nega-
tive results were repeated at least twice.
Results
Immunohistochemical analyses for basic calponin
Table 1 summarizes the data on immunohistochem-
istry of basic calponin and a -SMA in soft tissue
sarcomas.Among 65 malignant tumors, 6 of 14 (43%)
synovial sarcomas showed cytoplasmic immunoreac-
tivity of basic calponin. The basic calponin expres-
sion was also detected in 6 of 8 (75%)
leiomyosarcomas, 1 of 11 (9%) malignant ® brous
histiocytomas (MFHs), 1 of 8 (13%) liposarcomas,
and 1 of 7 (14%) malignant schwannomas.The frac-
tions of calponin-positive tumor cells were ranged
from more than 90% to as low as 10± 20% in synovial
sarcoma and leiomyosarcoma samples. Calponin-
positive tumor cells in synovial sarcomas showed a
spindle cell feature (Fig. 1(a,b)), with no immunore-
activity to epithelial markers such as cytokeratin and
epithelial membrane antigen (data not shown). The
remaining eight synovial sarcomas lacked immunore-
activity for calponin (Fig. 1(c)). There were no
apparent differences in tumor size or histologic
subtype between calponin-positive and calponin-
negative synovial sarcomas (Table 2).
Calponin-positive leiomyosarcomas tended to show
an orderly fascicular pattern and little pleomorphism
of tumor cells (Fig. 1(d)). The histology of two
calponin-negative leiomyosarcomas was an anaplastic
type with less fascicular pattern than the calponin-
positive tumors, but they showed immunoreactivity
for a -SMA (10± 45% positive cells). One MFH, one
liposarcoma, and one malignant schwannoma, showed
heterogeneous staining for basic calponin (10± 20%
positive cells). Rhabdomyosarcoma (Fig. 1(e)),
alveolar soft-part sarcoma, dermato® brosarcomas
protuberans (Fig. 1(f)), angiosarcoma, epithelioid
sarcoma, and the majority of MFHs, liposarcomas,
and malignant schwannomas lacked basic calponin
immunoreactivity. Notably, in contrast to MFH and
Table 2. Clinicopathological data of the patients with synovial sarcoma
No.
Calponin
expression* Age Sex Location
Tumor
size**
Histologic
subtype
1 (++) 26 F leg 1 biphasic
2 (++) 45 M hand 1 monophasic
3 (++) 45 M inguinal 2 biphasic
4 (+) 20 F thigh 3 monophasic
5 (+) 51 F chest wall 1 monophasic
6 (+) 57 M foot 2 monophasic
7 (- ) 61 M forearm 2 monophasic
8 (- ) 12 F inguinal 2 monophasic
9 (- ) 25 F chest wall 1 biphasic
10 (- ) 27 F thigh 1 monophasic
11 (- ) 14 M popliteal 2 monophasic
12 (- ) 13 F buttock 3 monophasic
13 (- ) 37 F calf 1 biphasic
14 (- ) 36 M buttock 2 monophasic
*(++); 50± 95% positive cells, (+); 10± 45% positive cells; (± ); less than 10% positive cells.
**1; <5 cm, 2; 5± 10 cm; 3; >10 cm.
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110 Hidefumi Ono et al.leiomyosarcoma, immunoreactivity for a -SMA was
not detected in any calponin-positive synovial
sarcomas.
Expression of calponin isoforms and other smooth muscle
markers in synovial sarcomas
Figure 2 shows the results of RT-PCR analyses for
the representative synovial sarcomas with negative
and positive immunoreactivity for basic calponin, and
for a clonal synovial sarcoma cell line (HS-SY-II).
The mRNA transcript of the SYT-SSX fusion gene
was detected in both of the two synovial sarcoma
tissues. The mRNA transcript of the basic calponin
gene was expressed in the case with positive immuno-
reactivity for basic calponin, but reduced in the case
with negative immunoreactivity for basic calponin,
indicating a correlation between the intensity of
immunohistochemical staining of basic calponin and
the expression levels of its mRNA transcript. The
HS-SY-II cells also expressed the basic calponin
mRNA transcript. The mRNAs for neutral calponin
and SM22a were uniformly expressed in the two
synovial sarcomas, but acidic calponin mRNA
transcript was reduced. In HS-SY-II cells, all calponin
isoforms and SM22a were expressed.
Discussion
Expression of smooth muscle calponin in a subset of
synovial sarcomas provides the ® rst evidence that this
gene can be expressed in soft-tissue tumors that lack
the features of smooth-muscle or myo® broblast
differentiation. Synovial sarcomas also expressed the
mRNA transcript of another smooth muscle-speci® c
gene, SM22a , suggesting a lineage relationship
between synovial sarcoma cells and smooth muscle-
like mesenchymal cells.
Recently, we have also detected expression of basic
calponin and smooth muscle-speci® c genes in a subset
of human osteosarcomas,
21 suggesting a lineage
relationship between smooth muscle-like cells and
osteoblasts. Calci® cation, an unlikely event in other
soft-tissue sarcomas, is a well-known feature of syno-
vial sarcoma occurring in approximately 30% of the
cases.
27 Furthermore, Milchgrub et al. found that
synovial sarcoma may produce tumorous osteoid
and bone formation rather than the metaplastic bone
and proposed a close relationship between osteob-
lasts and synovial sarcoma cells.
28 The fact that
smooth muscle speci® c genes are commonly expressed
in osteosarcoma and synovial sarcoma may support
their hypothesis.
Another unique feature of synovial sarcoma is
expression of epithelial markers.
1 Expression of both
epithelial and smooth muscle markers suggests that
histogenesis of synovial sarcoma may be related to
myoepithelial cells which present both
phenotypes.
16,17 Basic calponin expression holds
promise as a new diagnostic marker that enables
differential diagnosis of soft tissue sarcomas,
particularly in distinguishing certain cases of calponin-
producing synovial sarcomas from undifferentiated
spindle cell sarcomas. In other words, a basic calponin-
positive and a -SMA-negative spindle cell tumor in
immunohistochemistry may favor a diagnosis of syno-
vial sarcoma.
Basic calponin is not only a smooth muscle specific
gene, but also a cell proliferation-related gene involved
in the regulation of cell shape via the actin cytoskel-
eton.
29,30 Of particular interest is the ® nding that the
N-terminal region of basic calponin shares a
characteristic domain structure termed `calponin
homology’ or CH-domain with the molecules essential
for signal transduction of the Ras superfamily of
Fig. 2 (a) Detection of SYT-SSX fusion gene expression in synovial sarcoma by RT-PCR analysis. Lane 1: synovial sarcoma (Case
8) (basic calponin immunostaining; ± . Lane 2: synovial sarcoma (Case 1) (basic calponin immunostaining; ++), PCR product of the
fusion gene was 585 bp in size. (b) Detection of basic, neutral and acidic calponins, and SM22a expression in synovial sarcomas by
RT-PCR analysis. Lane 1: synovial sarcoma (Case 8) (basic calponin immunostaining; ± ). Lane 2: synovial sarcoma (Case 1) (basic
calponin immunostaining; ++). Lane 3: HS-SY-II cells during proliferation.
Calponin in synovial sarcoma 111GTPase proteins such as Vav proto-oncogene product
and IQGAP1.
31,32 Removal of the N-terminal 67
residues of the Vav protein, which contains a region
of the CH-domain, is sufficient to activate the
transforming potential of the Vav proto-oncogene
product.
33,34 These ® ndings suggest that basic
calponin may control actin cytoskeleton,and therefore
may exert in¯ uence on proliferation, the transformed
phenotype and the metastatic potential of the tumor
cells. It is also possible that loss of the inhibitory
action of calponin on actin± myosin interaction may
promote the migration and cytokinesis of the tumor
cells, and thus may also in¯ uence their proliferation
and metastatic potential.
With regard to osteosarcoma patients, a poorer
clinical outcome was correlated with loss of basic
calponin expression.
21Therefore, analyses on expres-
sion of basic calponin in synovial sarcomas seem to
be important for understanding the biological behav-
iors.
In conclusion, basic calponin expression in a subset
of synovial sarcomas may provide us with some leads
to solve the histogenesis of these tumors. Further
research will examine whether the status of basic
calponin expression in synovial sarcomas is a new
and independent prognostic factor that may help in
the subclassi® cation of these tumor types.
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